Clinical Trial Update: RSV-F Vaccine Dose Ranging Study in Young Women [Phase 2]

View source ↗

Summary

The RSV-F vaccine dose-ranging study in young women (Phase 2) has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syncytial Virus Infection

Drugs mentioned

• RSV F vaccine (RSV F protein vaccine)

Snippet

Sponsor: Novavax | Conditions: Respiratory Syncytial Virus (RSV) | Phase 2 | Status: COMPLETED